Sarcoma
Conditions
Keywords
Sarcoma, Soft Tissue Sarcoma
Brief summary
This study is for adult subjects with advanced tissue sarcoma. The study involves the drugs Pazopanib (Votrient), Gemcitabine (Gemzar), and Docetaxel (Taxotere). The purpose of this study is to test the effectiveness and safety of Gemcitabine and Pazopanib compared with Gemcitabine and Docetaxel in participants with soft tissue sarcoma.
Detailed description
The purpose of this study is to test the effectiveness and safety of Gemcitabine and Pazopanib compared with Gemcitabine and Docetaxel in participants with soft tissue sarcoma. Screening tests will be done to ensure subjects are eligible to participate in this study. If the exams, tests and procedures show that subjects can be in the study, and they choose to take part, then they will be randomized into one of the two study groups: Group 1 or Group 2. Subjects in Group 1 will receive Gemcitabine 1000 mg/m2 intravenously (directly into a vein) on Day 1 and Day 8 and Pazopanib 800mg by mouth daily. Subjects in Group 2 will receive Gemcitabine 900 mg/m2 intravenously on Day 1 and Day 8 and Docetaxel 100 mg/m2 intravenously on Day 8. Both groups will be in 21 day cycles. Both groups will be asked to complete quality of life questionnaires, on their first visit, then at 6 weeks (2nd cycle), 18 weeks (6th cycle) and at the end of study treatment. Subjects will be followed for up to 2 years.
Interventions
DRUGGemcitabine and Pazopanib
Gemcitabine 1000 mg/m2 by IV on day 1 and day 8 of a 21 day cycle. Pazopanib 800 mg by oral tablet daily for a 21 day cycle.
Gemcitabine 900 mg/m2 by IV on day 1 and day 8 of a 21 day cycle. Docetaxel 100 mg/m2 by IV on day 8 of a 21 day cycle.
Sponsors
Novartis
Medical University of South Carolina
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Subjects must provide written informed consent prior to performance of study-specific procedures or assessments, and must be willing to comply with treatment and follow up. Procedures conducted as part of the subject's routine clinical management (e.g., blood count, imaging study) and obtained prior to signing of informed consent may be utilized for screening or baseline purposes provided these procedures are conducted as specified in the protocol. * Age ≥ 18 years or legal age of consent if greater than 18 years. * Histologically or cytologically confirmed diagnosis of sarcoma of soft tissue. (Patients with liposarcoma, bone sarcoma or GIST will be excluded). * Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. * Subjects must have metastatic and/or locally advanced or locally recurrent disease that is not amenable to curative surgical resection. * A minimum of 1 and a maximum of 3 prior chemotherapy regimens for recurrent/metastatic disease. Patients eligible for an anthracycline should have received a prior anthracycline containing regimen. Patients who decline or are not eligible for anthracycline treatment may be considered for this protocol as a first line treatment. * Patients must have measurable disease by RECIST 1.1. or cutaneous disease amenable to serial measurements should be present. Measurable disease (a 'target' lesion) is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded). Each lesion must be ≥ 10 mm when measured by CT (CT scan slice thickness no greater than 5 mm); ≥ 10 mm caliper measurement by clinical exam (lesions which cannot be accurately measured with calipers should be recorded as non-measurable); and ≥ 20 mm by chest x-ray. * Able to swallow and retain oral medication. * Adequate organ system function * A female is eligible to enter and participate in this study if she is of: * Non-childbearing potential (i.e., physiologically incapable of becoming pregnant), including any female who has had: * A hysterectomy * A bilateral oophorectomy (ovariectomy) * A bilateral tubal ligation * Is post-menopausal Subjects not using hormone replacement therapy (HRT) must have experienced total cessation of menses for ≥ 1 year and be greater than 45 years in age, OR, in questionable cases, have a follicle stimulating hormone (FSH) value \> 40 mIU/mL and an estradiol value \< 40pg/mL (\< 140 pmol/L). Subjects using HRT must have experienced total cessation of menses for \>= 1 year and be greater than 45 years of age OR have had documented evidence of menopause based on FSH and estradiol concentrations prior to initiation of HRT. \-- Childbearing potential, including any female who has had a negative serum pregnancy test within 2 weeks prior to the first dose of study treatment, preferably as close to the first dose as possible, and agrees to use adequate contraception. Acceptable contraceptive methods, when used consistently and in accordance with both the product label and the instructions of the physician, are as follow: * Complete abstinence from sexual intercourse for 14 days before exposure to investigational product, through the dosing period, and for at least 21 days after the last dose of investigational product * Oral contraceptive, either combined or progestogen alone * Injectable progestogen * Implants of levonorgestrel * Estrogenic vaginal ring * Percutaneous contraceptive patches * Intrauterine device (IUD) or intrauterine system (IUS) with a documented failure rate of less than 1% per year * Male partner sterilization (vasectomy with documentation of azoospermia) prior to the female subject's entry into the study, and this male is the sole partner for that subject * Double barrier method: condom and an occlusive cap (diaphragm or cervical/vault caps) with a vaginal spermicidal agent (foam/gel/film/cream/suppository) Female subjects who are lactating should discontinue nursing prior to the first dose of study drug and should refrain from nursing throughout the treatment period and for 14 days following the last dose of study drug.
Exclusion criteria
* Prior therapy with pazopanib, gemcitabine or docetaxel. * Any concern for hypersensitivity to pazopanib, gemcitabine or docetaxel. * Prior malignancy. Note: Subjects who have had another malignancy and have been disease-free for 3 years, or subjects with a history of completely resected non-melanomatous skin carcinoma or successfully treated in situ carcinoma are eligible. * History or clinical evidence of central nervous system (CNS) metastases or leptomeningeal carcinomatosis, except for individuals who have previously-treated CNS metastases, are asymptomatic, and have had no requirement for steroids or anti-seizure medication for 6 months prior to first dose of study drug. Screening with CNS imaging studies (computed tomography \[CT\] or magnetic resonance imaging \[MRI\]) is required only if clinically indicated or if the subject has a history of CNS metastases. * Clinically significant gastrointestinal abnormalities that may increase the risk for gastrointestinal bleeding including, but not limited to: * Active peptic ulcer disease * Known intraluminal metastatic lesion/s with risk of bleeding * Inflammatory bowel disease (e.g. ulcerative colitis, Crohn's disease), or other gastrointestinal conditions with increased risk of perforation * History of abdominal fistula, gastrointestinal perforation, or intra abdominal abscess within 28 days prior to beginning study treatment. Clinically significant gastrointestinal abnormalities that may affect absorption of investigational product including, but not limited to: * Malabsorption syndrome * Major resection of the stomach or small bowel and experiencing the dumping syndrome. * Presence of uncontrolled infection. * Prior mediastinal radiation * Corrected QT interval (QTc) \> 480 msecs using Bazett's formula. * History of any one or more of the following conditions within the past 6 months: * Cardiac angioplasty or stenting * Myocardial infarction * Unstable angina * Coronary artery bypass graft surgery * Symptomatic peripheral vascular disease * Pneumonitis * Class III or IV congestive heart failure, as defined by the New York Heart Association (NYHA) (Appendix D). * Poorly controlled hypertension \[defined as systolic blood pressure (SBP) of ≥ 150 mmHg or diastolic blood pressure (DBP) of ≥ 90mmHg\]. Note: Initiation or adjustment of antihypertensive medication(s) is permitted prior to study entry. BP must be re-assessed on two occasions that are separated by a minimum of 1 hour; on each of these occasions, the mean (of 3 readings) SBP/DBP values from each BP assessment must be \< 150/90 mmHg in order for a subject to be eligible for the study. -History of cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months. Note: Subjects with recent DVT who have been treated with therapeutic anti-coagulating agents for at least 6 weeks prior to registration and are fully anti-coagulated are eligible. * Prior major surgery or trauma within 28 days prior to first dose of study drug and/or presence of any non-healing wound, fracture, or ulcer (procedures such as catheter placement not considered to be major). * Evidence of active bleeding or bleeding diathesis. * Known endobronchial lesions and/or lesions infiltrating major pulmonary Hemoptysis in excess of 2.5 mL (or one half teaspoon) within 8 weeks of first dose of study drug. * Any serious and/or unstable pre-existing medical, psychiatric, or other condition that could interfere with subject's safety, provision of informed consent, or compliance to study procedures. * Unable or unwilling to discontinue use of prohibited medications listed in Section 5.2.3 for at least 14 days or five half-lives of a drug (whichever is longer) prior to the first dose of study drug and for the duration of the study. * Treatment with any of the following anti-cancer or non-oncologic investigational therapies: * radiation therapy, surgery or tumor embolization within 14 days prior to registration. * chemotherapy, immunotherapy, biologic therapy, investigational therapy or hormonal therapy within 14 days or 2.5 half-lives of a drug (whichever is longer) prior to registration. * non-oncologic investigational products within 30 days or 5 halflives, whichever is longer. * Any ongoing toxicity from prior anti-cancer therapy that is \>Grade 1 and/or that is progressing in severity, except alopecia.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Average Number of Months of Progression-free Survival | minimum of 18 months | To estimate the PFS of the combination of G+P or G+T in patients with metastatic and/or locally advanced or recurrent STS. Progression free survival is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first. |
| Rate of Participants With Grade 3 or Higher Toxicity | 30 days post end of treatment | Toxicity is graded according to the CTCAE v 4. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Hazard Ratio | minimum of 18 months | Hazard ratio is defined as the rate of survival in the experimental group versus the standard of care group. A hazard ratio of greater than one or less than one means that survival was better in one of the groups. |
| Average Score of Quality of Life | Baseline, Cycle 2, Cycle 6 and End of Treatment | To estimate the quality of life of patient with metastatic an/or locally advanced recurrent STS using the Quality of Life Questionnaire (QLQ-C30). The QLQ-C30 is scored on a scale from 0-100 with 0 indicating never and 100 indicating always in regard the the participants' experience of fatigue, nausea/vomiting, pain, disponae, insomnia, appetite loss, constipation, diarrhea, financial concerns at 4 time points through the study. |
| Response Rate | minimum of 18 months | Response rate is defined as follows: Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Experimental Patients in Group 1 will get Gemcitabine 1000 mg/m2 intravenously on Day 1 and Day 8 and Pazopanib 800mg by mouth daily on a 21 day cycle. Cycles will continue until disease progression or patient withdrawal.
Gemcitabine and Pazopanib: Gemcitabine 1000 mg/m2 by IV on day 1 and day 8 of a 21 day cycle.
Pazopanib 800 mg by oral tablet daily for a 21 day cycle. | 45 |
| Standard of Care Patients in Group 2 will get Gemcitabine 900 mg/m2 intravenously on Day 1 and Day 8. Additionally on Day 8, patients will have Docetaxel 100 mg/m2 given intravenously. on a 21 day cycle. If disease progression occurs on this treatment, patients will have the option to receive treatment with Gemcitabine and Pazopanib (group 1).
Gemcitabine and Docetaxel: Gemcitabine 900 mg/m2 by IV on day 1 and day 8 of a 21 day cycle.
Docetaxel 100 mg/m2 by IV on day 8 of a 21 day cycle. | 45 |
| Total | 90 |
Baseline characteristics
| Characteristic | Standard of Care | Total | Experimental |
|---|---|---|---|
| Age, Continuous | 54.6 years STANDARD_DEVIATION 14.1 | 56.27 years STANDARD_DEVIATION 13.95 | 57.93 years STANDARD_DEVIATION 13.76 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 2 Participants | 6 Participants | 4 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 43 Participants | 80 Participants | 37 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 4 Participants | 4 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 2 Participants | 2 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 8 Participants | 11 Participants | 3 Participants |
| Race (NIH/OMB) More than one race | 2 Participants | 4 Participants | 2 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 4 Participants | 4 Participants |
| Race (NIH/OMB) White | 33 Participants | 69 Participants | 36 Participants |
| Sex: Female, Male Female | 22 Participants | 46 Participants | 24 Participants |
| Sex: Female, Male Male | 23 Participants | 44 Participants | 21 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 32 / 45 | 30 / 45 |
| other Total, other adverse events | 45 / 45 | 45 / 45 |
| serious Total, serious adverse events | 28 / 45 | 31 / 45 |
Outcome results
Primary
Average Number of Months of Progression-free Survival
To estimate the PFS of the combination of G+P or G+T in patients with metastatic and/or locally advanced or recurrent STS. Progression free survival is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first.
Time frame: minimum of 18 months
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Experimental | Average Number of Months of Progression-free Survival | 4.1 months |
| Standard of Care | Average Number of Months of Progression-free Survival | 4.1 months |
Primary
Rate of Participants With Grade 3 or Higher Toxicity
Toxicity is graded according to the CTCAE v 4.
Time frame: 30 days post end of treatment
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Experimental | Rate of Participants With Grade 3 or Higher Toxicity | 39 Participants |
| Standard of Care | Rate of Participants With Grade 3 or Higher Toxicity | 39 Participants |
Secondary
Average Score of Quality of Life
To estimate the quality of life of patient with metastatic an/or locally advanced recurrent STS using the Quality of Life Questionnaire (QLQ-C30). The QLQ-C30 is scored on a scale from 0-100 with 0 indicating never and 100 indicating always in regard the the participants' experience of fatigue, nausea/vomiting, pain, disponae, insomnia, appetite loss, constipation, diarrhea, financial concerns at 4 time points through the study.
Time frame: Baseline, Cycle 2, Cycle 6 and End of Treatment
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Experimental | Average Score of Quality of Life | Fatigue at baseline | 61.79 score on a scale | Standard Deviation 27.89 |
| Experimental | Average Score of Quality of Life | Fatigue at cycle 6 | 64.44 score on a scale | Standard Deviation 11.48 |
| Experimental | Average Score of Quality of Life | Fatigue at cycle 2 | 52.89 score on a scale | Standard Deviation 23.85 |
| Experimental | Average Score of Quality of Life | Nausea/vommiting at cycle 6 | 86.67 score on a scale | Standard Deviation 7.03 |
| Experimental | Average Score of Quality of Life | Pain at cycle 6 | 80.00 score on a scale | Standard Deviation 23.31 |
| Experimental | Average Score of Quality of Life | Insomnia at baseline | 45.53 score on a scale | Standard Deviation 39.97 |
| Experimental | Average Score of Quality of Life | Dyspnoae at cycle 6 | 10.00 score on a scale | Standard Deviation 16.1 |
| Experimental | Average Score of Quality of Life | Nausea/Vomitting at cycle 2 | 80.67 score on a scale | Standard Deviation 17.13 |
| Experimental | Average Score of Quality of Life | Insomnia at cycle 6 | 23.33 score on a scale | Standard Deviation 16.1 |
| Experimental | Average Score of Quality of Life | Pain at baseline | 61.38 score on a scale | Standard Deviation 32.8 |
| Experimental | Average Score of Quality of Life | Appetite loss at cycle 6 | 26.67 score on a scale | Standard Deviation 34.43 |
| Experimental | Average Score of Quality of Life | Pain at cycle 2 | 66.00 score on a scale | Standard Deviation 26.56 |
| Experimental | Average Score of Quality of Life | Constipation at cycle 6 | 13.33 score on a scale | Standard Deviation 17.21 |
| Experimental | Average Score of Quality of Life | Appetite loss at baseline | 22.76 score on a scale | Standard Deviation 32.01 |
| Experimental | Average Score of Quality of Life | Insomnia at end of study | 48.28 score on a scale | Standard Deviation 36.28 |
| Experimental | Average Score of Quality of Life | Diarrhea at cycle 6 | 36.67 score on a scale | Standard Deviation 24.6 |
| Experimental | Average Score of Quality of Life | Dyspnoae at cycle 2 | 24.00 score on a scale | Standard Deviation 24.57 |
| Experimental | Average Score of Quality of Life | Financial at cycle 6 | 23.33 score on a scale | Standard Deviation 31.62 |
| Experimental | Average Score of Quality of Life | Nausea/Vommiting at baseline | 91.06 score on a scale | Standard Deviation 14.48 |
| Experimental | Average Score of Quality of Life | Fatigue at end of study | 49.81 score on a scale | Standard Deviation 22.74 |
| Experimental | Average Score of Quality of Life | Insomnia at cycle 2 | 42.67 score on a scale | Standard Deviation 34.05 |
| Experimental | Average Score of Quality of Life | Nausea/vomitting at end of study | 75.86 score on a scale | Standard Deviation 23.82 |
| Experimental | Average Score of Quality of Life | Constipation at baseline | 14.63 score on a scale | Standard Deviation 26.92 |
| Experimental | Average Score of Quality of Life | Pain at end of study | 53.45 score on a scale | Standard Deviation 32.85 |
| Experimental | Average Score of Quality of Life | Appetite loss at cycle 2 | 36.11 score on a scale | Standard Deviation 32.48 |
| Experimental | Average Score of Quality of Life | Dysponae at end of study | 31.03 score on a scale | Standard Deviation 33.25 |
| Experimental | Average Score of Quality of Life | Dysponae at baseline | 22.76 score on a scale | Standard Deviation 32.86 |
| Experimental | Average Score of Quality of Life | Constipation at cycle 2 | 13.33 score on a scale | Standard Deviation 21.52 |
| Experimental | Average Score of Quality of Life | Appetite loss at end of study | 37.93 score on a scale | Standard Deviation 33 |
| Experimental | Average Score of Quality of Life | Diarrhea at baseline | 4.88 score on a scale | Standard Deviation 11.93 |
| Experimental | Average Score of Quality of Life | Constipation at end of study | 17.24 score on a scale | Standard Deviation 24.59 |
| Experimental | Average Score of Quality of Life | Diarrhea at cycle 2 | 4.88 score on a scale | Standard Deviation 11.93 |
| Experimental | Average Score of Quality of Life | Diarrhea at end of study | 21.43 score on a scale | Standard Deviation 22.62 |
| Experimental | Average Score of Quality of Life | Financial at baseline | 37.40 score on a scale | Standard Deviation 40.96 |
| Experimental | Average Score of Quality of Life | Financial at end of study | 39.60 score on a scale | Standard Deviation 39.29 |
| Experimental | Average Score of Quality of Life | Financial at cycle 2 | 26.67 score on a scale | Standard Deviation 34.69 |
| Standard of Care | Average Score of Quality of Life | Financial at end of study | 29.17 score on a scale | Standard Deviation 33.06 |
| Standard of Care | Average Score of Quality of Life | Nausea/vommiting at cycle 6 | 8.05 score on a scale | Standard Deviation 95 |
| Standard of Care | Average Score of Quality of Life | Fatigue at baseline | 67.12 score on a scale | Standard Deviation 23.44 |
| Standard of Care | Average Score of Quality of Life | Nausea/Vommiting at baseline | 90.99 score on a scale | Standard Deviation 16.94 |
| Standard of Care | Average Score of Quality of Life | Pain at baseline | 74.77 score on a scale | Standard Deviation 25.65 |
| Standard of Care | Average Score of Quality of Life | Dysponae at baseline | 21.62 score on a scale | Standard Deviation 29.62 |
| Standard of Care | Average Score of Quality of Life | Insomnia at baseline | 36.04 score on a scale | Standard Deviation 30.81 |
| Standard of Care | Average Score of Quality of Life | Appetite loss at baseline | 15.32 score on a scale | Standard Deviation 26.75 |
| Standard of Care | Average Score of Quality of Life | Constipation at baseline | 15.32 score on a scale | Standard Deviation 23.03 |
| Standard of Care | Average Score of Quality of Life | Financial at baseline | 32.43 score on a scale | Standard Deviation 34.68 |
| Standard of Care | Average Score of Quality of Life | Fatigue at cycle 2 | 55.09 score on a scale | Standard Deviation 25.06 |
| Standard of Care | Average Score of Quality of Life | Nausea/Vomitting at cycle 2 | 93.75 score on a scale | Standard Deviation 9.6 |
| Standard of Care | Average Score of Quality of Life | Pain at cycle 2 | 83.33 score on a scale | Standard Deviation 20.85 |
| Standard of Care | Average Score of Quality of Life | Dyspnoae at cycle 2 | 26.39 score on a scale | Standard Deviation 24.04 |
| Standard of Care | Average Score of Quality of Life | Insomnia at cycle 2 | 38.89 score on a scale | Standard Deviation 28.94 |
| Standard of Care | Average Score of Quality of Life | Appetite loss at cycle 2 | 26.39 score on a scale | Standard Deviation 32.57 |
| Standard of Care | Average Score of Quality of Life | Constipation at cycle 2 | 23.61 score on a scale | Standard Deviation 25.02 |
| Standard of Care | Average Score of Quality of Life | Diarrhea at cycle 2 | 8.11 score on a scale | Standard Deviation 16.49 |
| Standard of Care | Average Score of Quality of Life | Financial at cycle 2 | 22.22 score on a scale | Standard Deviation 27.22 |
| Standard of Care | Average Score of Quality of Life | Fatigue at cycle 6 | 51.11 score on a scale | Standard Deviation 30.63 |
| Standard of Care | Average Score of Quality of Life | Pain at cycle 6 | 78.33 score on a scale | Standard Deviation 30.48 |
| Standard of Care | Average Score of Quality of Life | Dyspnoae at cycle 6 | 43.33 score on a scale | Standard Deviation 22.5 |
| Standard of Care | Average Score of Quality of Life | Insomnia at cycle 6 | 33.33 score on a scale | Standard Deviation 27.22 |
| Standard of Care | Average Score of Quality of Life | Appetite loss at cycle 6 | 30.00 score on a scale | Standard Deviation 24.6 |
| Standard of Care | Average Score of Quality of Life | Constipation at cycle 6 | 13.33 score on a scale | Standard Deviation 23.31 |
| Standard of Care | Average Score of Quality of Life | Diarrhea at cycle 6 | 20.00 score on a scale | Standard Deviation 23.31 |
| Standard of Care | Average Score of Quality of Life | Financial at cycle 6 | 20.00 score on a scale | Standard Deviation 23.31 |
| Standard of Care | Average Score of Quality of Life | Fatigue at end of study | 49.77 score on a scale | Standard Deviation 25.77 |
| Standard of Care | Average Score of Quality of Life | Nausea/vomitting at end of study | 92.36 score on a scale | Standard Deviation 12.02 |
| Standard of Care | Average Score of Quality of Life | Pain at end of study | 72.92 score on a scale | Standard Deviation 24.48 |
| Standard of Care | Average Score of Quality of Life | Dysponae at end of study | 34.72 score on a scale | Standard Deviation 28.62 |
| Standard of Care | Average Score of Quality of Life | Insomnia at end of study | 37.50 score on a scale | Standard Deviation 26.58 |
| Standard of Care | Average Score of Quality of Life | Appetite loss at end of study | 23.61 score on a scale | Standard Deviation 28.62 |
| Standard of Care | Average Score of Quality of Life | Constipation at end of study | 29.17 score on a scale | Standard Deviation 30 |
| Standard of Care | Average Score of Quality of Life | Diarrhea at end of study | 15.28 score on a scale | Standard Deviation 24.04 |
| Standard of Care | Average Score of Quality of Life | Diarrhea at baseline | 8.11 score on a scale | Standard Deviation 16.49 |
Secondary
Hazard Ratio
Hazard ratio is defined as the rate of survival in the experimental group versus the standard of care group. A hazard ratio of greater than one or less than one means that survival was better in one of the groups.
Time frame: minimum of 18 months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Experimental | Hazard Ratio | 1.2 hazard ratio |
| Standard of Care | Hazard Ratio | NA hazard ratio |
Secondary
Response Rate
Response rate is defined as follows: Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study
Time frame: minimum of 18 months
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Experimental | Response Rate | Complete Response | 0 Participants |
| Experimental | Response Rate | Partial Response | 5 Participants |
| Experimental | Response Rate | Stable Disease | 24 Participants |
| Experimental | Response Rate | Progressive Disease | 14 Participants |
| Standard of Care | Response Rate | Progressive Disease | 16 Participants |
| Standard of Care | Response Rate | Complete Response | 0 Participants |
| Standard of Care | Response Rate | Stable Disease | 21 Participants |
| Standard of Care | Response Rate | Partial Response | 8 Participants |